메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by
- 김갑성 기자
- 2025-11-25 17:00
FROM MEDICAL SUPPLIER TO MULTI-INDUSTRY LEADER: LIVINGSTONE INTERNATIONAL'S UNIQUE GROWTH STRATEGY

SYDNEY, Nov. 25, 2025 -- One of Australia's largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries. Livingstone International supplies more than 65,000 essential health, hygiene, education, beauty, and hospitality products to industries including aged care, schools and universities, hair and skin clinics, pharmacy, dental, mining, and government. Livingstone International Managing Director, Daniel Linn, said the company has no
- 김갑성 기자
- 2025-11-25 05:00
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization

[ 메디채널 김갑성 기자 ] The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating ad
- 김갑성 기자
- 2025-11-25 00:30
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy and NEW YORK, Nov. 24, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology
- 김갑성 기자
- 2025-11-24 23:34
Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release

- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer's disease. "While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease," said Joanne Pike, DrPH, Alzheimer's A
- 김갑성 기자
- 2025-11-24 23:19
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season

Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public in Italy. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon FLORENCE, Italy, Nov. 24, 2025 -- Ten international talents, differing in both age and experience but united by the desire to make a difference, both in Italy and Europe. After the opening match of the 2025/2026 season, the new roster of the Volpi Rosse Menarini wheelchair basketball team was officially presented today, ready to start competing in the FIPIC Serie A championsh
- 황정호 기자
- 2025-11-24 22:40
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, in
- 김갑성 기자
- 2025-11-24 22:00
Pinnacle Food Announces New Strategic Initiative to Expand its Smart Agriculture Innovation Platform

VANCOUVER, BC, Nov. 24, 2025 -- Pinnacle Food Group Limited (NASDAQ:PFAI) announced a strategic initiative to establish a bioengineering and testing laboratory. The Company is exploring applied bioengineering initiatives to further expand its smart agriculture innovation platform into bioengineering applications, supporting its future growth. To support the lab's development, Pinnacle Food Inc., a wholly owned subsidiary of Pinnacle Food Group Limited, has entered into a consulting agreement with Bioboost Synbio Consulting Inc. ("Bioboost"), a leading Br
- 황정호 기자
- 2025-11-24 21:00
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

CHENGDU, China, Nov. 24, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC), has demonstrated a statistically significant and clinically meaningful improvemen
- 김갑성 기자
- 2025-11-24 20:00
Triple the Probiotics, Triple the Relief: Life-Space Launches Triple Strength Probiotics in Southeast Asia

Engineered by Australia's leading probiotics expert, this high CFU probiotic delivers the ultimate gut defense, helping to reduce gut transit time by up to 18 hours. SINGAPORE, Nov. 24, 2025 -- Life-Space, Australia's No.1 probiotic brand, proudly unveils Triple Strength Probiotics, a flash charged probiotic designed to deliver intensive gut health support for those with more demanding digestive needs. With 15 premium strains and three times the beneficial bacteria of regular Broad Spectrum Probiotic formulations, this high-strength solution delivering 96 billion CFU's per capsule repr
- 김갑성 기자
- 2025-11-24 18:29

이전

81 82 83 84 85 86 87 88 89 90

많이 본 기사

최근기사

2026-03-03_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 12시 20분